Aug 13, 2020 8:15am EDT Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Aug 05, 2020 1:57pm EDT Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Aug 05, 2020 8:37am EDT Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil
Jul 21, 2020 8:00am EDT Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment
Jul 16, 2020 8:00am EDT Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19
Jul 07, 2020 8:00am EDT Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia
Jun 25, 2020 8:00am EDT Algernon Receives Ethics Approval for U.S. Sites for 2b/3 Human Study of Ifenprodil for COVID-19
Jun 04, 2020 12:10pm EDT Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19
May 28, 2020 9:00am EDT Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD
May 26, 2020 8:49am EDT Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19
